Resistant leukemia treated with base-edited T cells
June 15, 2023 -- Three young patients with relapsed T-cell leukemia have now been treated with base-edited T cells, in an ongoing clinical trial collaboratively conducted by University College London (UCL) and Great Ormond Street Hospital for Children (GOSH). Read More
BioCentriq, Kytopen expand partnership on cell therapy manufacturing technology
June 6, 2023 -- BioCentriq, a contract development and manufacturing organization specializing in cell therapy, and Kytopen, a Massachusetts Institute of Technology-based startup, on Tuesday announced that they are expanding their partnership. Read More
Stem cell therapy targets brain metastatic melanomas
May 31, 2023 -- Twin stem cells acting in unison may activate the immune system to suppress metastatic melanoma tumor growth in the brain, according to Department of Defense-funded research, published Wednesday in Science Translational Medicine. The procedure prolonged survival in preclinical trials on mice, indicating that locally delivered immunotherapies may be beneficial in brain metastases treatment. Read More
FDA approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa
May 19, 2023 -- The U.S. Food and Drug Administration (FDA) said on Friday it has approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa (DEB) and with mutations in the collagen type VII alpha 1 chain (COL7A1) gene. Read More
Revvity, AstraZeneca ink license agreement for next-gen base editing tech
May 19, 2023 -- Revvity this week announced a nonexclusive license agreement with AstraZeneca for the technology underlying a next-generation modular gene editing platform. Read More
1
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter